Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Correction: Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy

  • Tal I. Arnon,
  • Gal Markel,
  • Ahuva Bar-Ilan,
  • Jacob Hanna,
  • Eyal Fima,
  • Fabrice Benchetrit,
  • Ruth Galili,
  • Adelheid Cerwenka,
  • Daniel Benharroch,
  • Netta Sion-Vardy,
  • Angel Porgador,
  • Ofer Mandelboim
  • Article
  • Metrics
  • Comments
  • Media Coverage

There are errors in Fig 4, “Summary of fusion protein treatment”. Fig 4a contains the wrong set of images for PBS (control) injected mice. Please see the corrected Fig 4 here.

thumbnail
Fig 4. Summary of fusion protein treatment.

(a) Visualization of tumor progression and distribution in vivo. The figure shows an image visualization of one representative animal of each treatment. The scale on the right of each figure describes the color map of the photon count. The integrated light emission (‘I’) is indicated in the left of each photo. (b) Summary of treatment effect. Table describes the overall effect of treatments, as shown in details in Fig 3.

https://doi.org/10.1371/journal.pone.0128052.g001

Reference

  1. 1. Arnon TI, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F, et al. (2008) Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy. PLoS ONE 3(5): e2150. pmid:18478075